

Literaturverzeichnis

Hamburger Ärzteblatt 02 | 2022

Seite 1

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 16: Altersbedingte Makuladegeneration.

Von PD Dr. Birthe Stemplewitz, Dr. Kais Al-Samir, PD Dr. Ulrich Schaudig

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS et al. Causes and prevalence of visual impairment among adults in the United States. *Archives of ophthalmology*. 2004;122(4):477-85.
2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *The Lancet Global health*. 2014;2(2):e106-16.
3. Mauschitz MM, Li JQ, Larsen PP, Köberlein-Neu J, Holz FG, Breteler MMB et al. [Epidemiology of severe visual impairment and blindness of old people in Germany]. *Ophthalmologie*. 2019;116(2):201-12.
4. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. *Br J Ophthalmol*. 2020;104(8):1077-84.
5. Lamin A, El Nokrashy A, Chandra S, Sivaprasad S. Association of Longitudinal Changes in Drusen Characteristics and Retinal Layer Volumes with Subsequent Subtype of Choroidal Neovascularisation. *Ophthalmic Res*. 2020;63(4):375-82.
6. Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, et al. Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. *Invest Ophthalmol Vis Sci*. 2018;59(8):3199-208.
7. Finger RP, Fleckenstein M, Holz FG, Scholl HP. Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2008;17(4):559-74.
8. Mitchell J, Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2004;13(6):1163-75.
9. Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. *BMJ open*. 2016;6(12):e011504.
10. Meyer-Ruesenberg B, Richard G. [New insights into the underestimated impairment of quality of life in age-related macular degeneration - a review of the literature]. *Klin Monbl Augenheilkd*. 2010;227(8):646-52.
11. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. *Can J Ophthalmol*. 2005;40(3):277-87.
12. García-Layana A, Cabrera-López F, García-Arumí J, Arias-Barquet L, Ruiz-Moreno JM. Early and intermediate age-related macular degeneration: update and clinical review. *Clinical interventions in aging*. 2017;12:1579-87.
13. Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Wride MA, Padilla M et al. Risk factors and biomarkers of age-related macular degeneration. *Progress in retinal and eye research*. 2016;54:64-102.
14. Shahid H, Khan JC, Cipriani V, Sepp T, Matharu BK, Bunce C et al. Age-related macular degeneration: the importance of family history as a risk factor. *Br J Ophthalmol*. 2012;96(3):427-31.
15. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. *Science*. 1991;254(5035):1178-81.
16. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. *The New England journal of medicine*. 2006;355(14):1419-31.
17. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *The New England journal of medicine*. 2006;355(14):1432-44.

Literaturverzeichnis

Hamburger Ärzteblatt 02 | 2022

Seite 2

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

18. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. *Exp Eye Res.* 2006;83(3):615-9.
19. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. *Ophthalmology.* 2012;119(7):1399-411.
20. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *The New England journal of medicine.* 2011;364(20):1897-908.
21. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. *Am J Ophthalmol.* 2012;153(2):209-13.e2.
22. Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. *European journal of ophthalmology.* 2021;31(2):600-6.
23. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). *Ophthalmology.* 2013;120(11):2292-9.
24. van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. *PLoS One.* 2018;13(5):e0197670.
25. Khanani AM, Callanan D, Dreyer R, Chen S, Howard JG, Hopkins JJ et al. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. *Ophthalmology Retina.* 2021;5(8):775-87.
26. Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. *Current opinion in ophthalmology.* 2020;31(3):215-21.
27. Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S et al. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. *JAMA ophthalmology.* 2020;138(9):964-72.
28. Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK et al. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. *Ophthalmology.* 2020;127(10):1331-44.
29. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Archives of ophthalmology.* 2001;119(10):1417-36.
30. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *Jama.* 2013;309(19):2005-15.
31. Lasertherapie von Drusen bei altersabhängiger Makuladegeneration (AMD) [press release]. 2018.
32. Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. *JAMA ophthalmology.* 2018;136(6):666-77.
33. Available from: <https://www.augenklinik-sulzbach.de/patienten/2behandlungsspektrum/makuladegeneration/142-neue-operationsmethoden-bei-amd>

Angaben zu möglichen Interessenkonflikten: keine

Literaturverzeichnis

Hamburger Ärzteblatt 02 | 2022

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 24 – 26: Perioperativer Umgang mit Gerinnungshemmern.

Von Dr. Randi M. Pose, Prof. Dr. Florian Langer, PD Dr. Hendrik Isbarn

1. Afshari A, Fenger-Eriksen C, Monreal M, Verhamme P. ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Mechanical prophylaxis. *Eur J Anaesthesiol.* 2018 Feb;35(2):112-115.
2. AWMF Leitlinie: S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE), 2. komplett überarbeitete Auflage, Stand: 15.10.2015. Registernummer 003 – 001. Online unter: <https://www.awmf.org/leitlinien/detail/II/003-001.html> (abgerufen am: 02.08.2021)
3. Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, Kahn SR, Rahman M, Rajasekhar A, Rogers FB, Smythe MA, Tikkinen KAO, Yates AJ, Baldeh T, Balduzzi S, Brożek JL, Ikobaltzeta IE, Johal H, Neumann I, Wiercioch W, Yepes-Nuñez JJ, Schünemann HJ, Dahm P. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv.* 2019 Dec 10;3(23):3898-3944.
4. Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, Graefen M, Huland H, Karakiewicz PI, Tilki D. Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. *BJU Int.* 2018 Nov;122(5):801-807.
5. Tikkinen KAO, Cartwright R, Gould MK, Naspro R, Novara G, Sandset PM, Violette PD, Guyatt GH. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2020. ISBN 978-94-92671-07-3.
6. AWMF Leitlinie: S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Register Nr. 065/002. Online unter: <https://www.awmf.org/leitlinien/detail/II/065-002.html> (abgerufen am: 02.08.2021)
7. National Guideline Centre (UK). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (UK); veröffentlicht: www.nice.org.uk/guidance/ng89 (abgerufen am 02.08.2021)
8. Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H. Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment. *World J Urol.* 2019 Dec;37(12):2657-2662.
9. Altiok E, Marx N. Orale Antikoagulation. Update zur Antikoagulation mit Vitamin-K-Antagonisten und nicht-Vitamin-K-abhängigen oralen Antikoagulanzen. *Dtsch Arztebl Int* 2018; 115: 776-83.
10. Fachinformation. MEDA Pharma GmbH & KG. Marcumar. Online unter: https://www.marcumar.de/fileadmin/media/Fachpublikum/Fachinformation_Marcumar.pdf (abgerufen am 06.08.2021)
11. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J.* 2017 Sep 21;38(36):2739-2791. PMID: 28886619.
12. Swinkels BM, de Mol BA, Kelder JC, Vermeulen FE, Ten Berg JM. Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60. *Neth Heart J.* 2015 Feb;23(2):111-5. PMID: PMC4315789.
13. Cetinkaya A, Poggenpohl J, Bramlage K, Hein S, Doss M, Bramlage P, Schönburg M, Richter M. Long-term outcome after mitral valve replacement using biological versus mechanical valves. *J Cardiothorac Surg.* 2019 Jun 28;14(1):120. PMID: PMC6599286.

Literaturverzeichnis

Hamburger Ärzteblatt 02 | 2022

Seite 4

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

14. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH. Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. *J Thromb Thrombolysis*. 2011 May;31(4):514-22. PMID: PMC3699194.
15. Tan CW, Wall M, Rosengart TK, Ghanta RK. How to bridge? Management of anticoagulation in patients with mechanical heart valves undergoing noncardiac surgical procedures. *J Thorac Cardiovasc Surg*. 2019 Jul;158(1):200-203. Epub 2018 Jul 20. PMID: 30107917.
16. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2020 Aug 29;ehaa612.
17. Rose DK, Bar B. Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents. *J Stroke Cerebrovasc Dis*. 2018 Aug;27(8):2049-2058.
18. Pose R, Langer F, Tennstedt P, Graefen M, Isbarn H. Management of Patients Receiving Direct Oral Anticoagulants Scheduled for Radical Prostatectomy: An Update of a Prospective Assessment. *Eur Urol Focus*. 2021 Jan 28;S2405-4569(21)00012-2.
19. Ellis G, John Camm A, Datta SN. Novel anticoagulants and antiplatelet agents; a guide for the urologist. *BJU Int*. 2015 Nov;116(5):687-96.
20. Busch MA, Kuhnert R. *Journal of Health Monitoring* ·2017 2(1)DOI 10.17886/RKI-GBE-2017-009. RKI. Online unter: https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsJ/FactSheets/JoHM_2017_01_gesundheitliche_lage4.pdf?__blob=publicationFile (abgerufen am 02.08.2021)
21. AWMF- S2e Leitlinie: Neue Thrombozyten Aggregationshemmer Einsatz in der Hausarztpraxis. Register-Nr. 053-041. Online unter: <https://www.awmf.org/leitlinien/detail/II/053-041.html> (abgerufen am 06.08.2021)
22. Plümer L, Seiffert M, Punke MA, Kersten JF, Blankenberg S, Zöllner C, Petzoldt M. Aspirin before elective surgery - stop or continue? A single-center cross-sectional study. *Dtsch Arztebl Int* 2017; 114: 473-80.

Angaben zu möglichen Interessenkonflikten: keine

S. 28 – 29: Der besondere Fall: Massiver Verschleiß einer Hüftgelenkendoprothese.

Von Prof. Dr. habil. Alexander Katzer, Dr. Wolf-Peter Niedermauntel, Jörg Rump

1. Katzer A, Niedermauntel W-P, Haack C, Rump J. Mittelfristige Ergebnisse mit der CFP-Prothese. *Orthopädische Praxis* 47. 2011;(8): 377-380.
2. Haasper C, Kendoff DO, Gebauer M, Akos Zahar A, Kreibich T, Suero EM, Gehrke T. Traumatic Stem Fractures in Short Stem THA - A Rare Case Series. *HSSJ* 2013;9: 86-89.
3. Katzer A, Löhr JF. Frühlockerung von Hüftgelenkendoprothesen. *Deutsches Ärzteblatt* 2003;100 (12): 784-790.
4. Steens W, Loehr JF, von Foerster G, Katzer A. Chronische Kobaltvergiftung in der Endoprothetik – ein Fallbericht. *Orthopäde* 2006;35: 860-864.
5. Müller M, Wassilew G, Perka C. Diagnostik und Behandlung von Abrieberkrankungen in der Hüftendoprothetik. *Z Orthop Unfall* 2015;153: 213-29.